ChristopherAlanSlapakMD

PubMed

• 48 citations
  A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.
  Saroj Vadhan-Raj, Rafat Abonour, Jonathan W. Goldman, David Smith, Christopher A. Slapak, Robert Ilaria, Ramon V. Tiu, Xuejing Wang, Sophie Callies, Joanne Cox, Jay Tu...> ;Journal of Hematology & Oncology. 2017 Mar 21
• 383 citations
  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
  Stephan Herbertz, J. Scott Sawyer, Anja Stauber, Ivelina Gueorguieva, Kyla Driscoll, Shawn T. Estrem, Ann Cleverly, Durisala Desaiah, Susan C. Guba, Karim A. Benhadji,...> ;Drug Design, Development and Therapy. 2015 Aug 10
• 27 citations
  Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma
  Kristen N. Ganjoo, Sven de Vos, Brad Pohlman, Ian W. Flinn, Andres Forero-Torres, Nathan Enas, Damien M. Cronier, Nam H. Dang, Kenneth A. Foon, Susan P. Carpenter, Chr...> ;Leukemia & Lymphoma. 2015 Jan 1
• 12 citations
  Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
  Noboru Yamamoto, Hiroshi Nokihara, Yasuhide Yamada, Kazunori Uenaka, Risa Sekiguchi, Takeshi Makiuchi, Christopher A. Slapak, Karim A. Benhadji, Tomohide Tamura> ;Cancer Chemotherapy and Pharmacology. 2013 Apr 25
• 48 citations
  Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Fo...
  Andres Forero-Torres, Sven de Vos, Brad Pohlman, Maksim Pashkevich, Damien M. Cronier, Nam H. Dang, Susan P. Carpenter, Allan Barrett W, James Nelson, Christopher A. S...> ;Clinical Cancer Research. 2012 Mar 1
• 35 citations
  Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors
  Stijn L.W. Koolen, Petronella O. Witteveen, Robert S. Jansen, Marlies H.G. Langenberg, Roelien H. Kronemeijer, Annemarie Nol, Ignacio Garcia-Ribas, Sophie Callies, Kar...> ;Clinical Cancer Research. 2011 Jul 13
• 16 citations
  A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors.
  George R. Simon, Robert Ilaria, Mika A. Sovak, Charles C. Williams, Eric B. Haura, Ann Cleverly, Amanda K. Sykes, Margaret M. Wagner, Dinesh P. de Alwis, Christopher A...> ;Cancer Chemotherapy and Pharmacology. 2011 Mar 23
• 72 citations
  Tumor Survivin is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof of Concept, First-in-Human Dose Study
  Denis C. Talbot, Malcolm R Ranson, Joanna Davies, Michael Lahn, Sophie Callies, Valerie Andre, Sunil Kadam, Michael Burgess, Christopher A. Slapak, Anna L. Olsen, Pete...> ;Clinical Cancer Research. 2010 Dec 15
• 53 citations
  Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
  Stephan A. Veltkamp, Robert S. Jansen, Sophie Callies, Dick Pluim, Carla Visseren-Grul, Hilde Rosing, Susanne Kloeker-Rhoades, Valerie Andre, Jos H. Beijnen, Christoph...> ;Clinical Cancer Research. 2008 Jun 1
• 192 citations
  Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
  Michael J. Robertson, Brad S. Kahl, Julie M. Vose, Sven De Vos, Mary Laughlin, Patrick Flynn, Kendrith M Rowland, Jose C. Cruz, Stuart L. Goldberg, Luna Musib, Christe...> ;Journal of Clinical Oncology. 2007 May 1
• 24 citations
  Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours
  Lyly H. Le, Malcolm J. Moore, Lillian L. Siu, Amit M. Oza, M. Maclean, B. Fisher, Ajai K. Chaudhary, Dinesh P. de Alwis, Christopher A. Slapak, Lesley Seymour> ;Cancer Chemotherapy and Pharmacology. 2005 Apr 5
• 55 citations
  Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies
  Paula M. Fracasso, Lori J. Goldstein, Dinesh P. de Alwis, Janet S. Rader, Matthew A. Arquette, Sherry A. Goodner, Lisa P. Wright, Carole L. Fears, Robert J. Gazak, Val...> ;Clinical Cancer Research. 2004 Nov 1
• 237 citations
  An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines
  Jennifer Diane Davidson, Liandong Ma, Michael Flagella, Sandaruwan Geeganage, Lawrence M. Gelbert, Christopher A. Slapak> ;Cancer Research. 2004 Jun 1
• 28 citations
  Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- bindin...
  Anne H. Dantzig, Robert L. Shepard, Susan E. Pratt, Linda B. Tabas, Peter Ambrose Lander, Liandong Ma, Donald C. Paul, Daniel C. Williams, Sheng-Bin Peng, Christopher ...> ;Biochemical Pharmacology. 2004 Mar 15
• 18 citations
  Identification and characterization of the canine multidrug resistance-associated protein.
  Liandong Ma, Susan E. Pratt, Jin Cao, Anne H. Dantzig, Robert E. Moore, Christopher A. Slapak> ;Molecular Cancer Therapeutics. 2002 Dec 1
• 86 citations
  A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with...
  Eric H Rubin, Dinesh P de Alwis, Isabelle Pouliquen, Lisa Green, Phil Marder, Yong Lin, Rita Musanti, Stephanie L Grospe, Sharon L Smith, Deborah L Toppmeyer, Judy Muc...> ;Clinical Cancer Research. 2002 Dec 1
• 27 citations
  A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells
  Yi Hu, Andrew G. Stephen, Jin Cao, Lee R. Tanzer, Christopher A. Slapak, Steadman D. Harrison, Viswanath Devanarayan, Anne H. Dantzig, James J. Starling, Leonard H. Ro...> ;International Journal of Cancer. 2002 Jan 10
• 19 citations
  Reversal of multidrug resistance with LY335979: functional analysis of P-glycoprotein-mediated transport activity and its modulation in vivo.
  Christopher A. Slapak, Julie L. Dahlheimer, David Piwnica-Worms> ;Journal of Clinical Pharmacology. 2001 Jul 1
• 54 citations
  Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells.
  Lisa J. Green, Philip Marder, Christopher A. Slapak> ;Biochemical Pharmacology. 2001 Jun 1
• 105 citations
  Abrogation of Mitochondrial Cytochrome c Release and Caspase-3 Activation in Acquired Multidrug Resistance
  Hiromi Kojima, Kazuya Endo, Hiroshi Moriyama, Yasuhiro Tanaka, Emad S. Alnemri, Christopher A. Slapak, Beverly A. Teicher, Donald Kufe, Rakesh Datta> ;The Journal of Biological Chemistry. 1998 Jul 3
• 117 citations
  Vesicular Anthracycline Accumulation in Doxorubicin-Selected U-937 Cells: Participation of Lysosomes
  Selwyn J. Hurwitz, Masanori Terashima, Nobuyuki Mizunuma, Christopher A. Slapak> ;Blood. 1997 May 15
• 20 citations
  Effect of glucose transport inhibitors on vincristine efflux in multidrug-resistant murine erythroleukaemia cells overexpressing the multidrug resistance-associated pr...
  Robin L. Martell, Christopher A. Slapak, Stuart B. Levy> ;British Journal of Cancer. 1997 Jan 1
• 4 citations
  Differential changes in genome structure and expression of the mdr gene family in multidrug-resistant murine erythroleukemia cell lines.
  Fracasso Pm, Christopher A. Slapak, Nair S, David E. Modrak, Michael Draper, Jean-Michel Lecerf, Stuart B. Levy> ;Oncology Research. 1997 Jan 1
• 9 citations
  Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP)
  Christopher A. Slapak, Robin L. Martell, Masanori Terashima, Stuart B. Levy> ;Biochemical Pharmacology. 1996 Nov 22
• 5 citations
  Expression of c-fos precedes MDR3 in vincristine and adriamycin selected multidrug resistant murine erythroleukemia cells.
  Alok Bhushan, Christopher A. Slapak, Stuart B. Levy, Thomas R. Tritton> ;Biochemical and Biophysical Research Communications. 1996 Sep 24
• Join now to see all